DNAzyme targeting c-jun suppresses skin cancer growth

Science Translational Medicine

Volumn 4, Issue 139, 2012, Pages

  Cai, Hong ^a   Santiago, Fernando S ^a   Prado Lourenco, Leonel ^a   Wang, Bo ^a,g   Patrikakis, Margaret ^a   Davenport, Miles P ^a   Maghzal, Ghassan J ^b   Stocker, Roland ^b   Parish, Christopher R ^c   Chong, Beng H ^a   Lieschke, Graham J ^d,h   Wong, Tak Wah ^e   Chesterman, Colin N ^a   Francis, Douglas J ^f   Moloney, Fergal J ^b,i   Barnetson, Ross St C ^b   Halliday, Gary M ^b   Khachigian, Levon M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Biology and Environment   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f DF Pre Clinical Services Pty Ltd   (Australia)

^g UNIVERSITY OF LETHBRIDGE   (Canada)

^h MONASH UNIVERSITY   (Australia)

ⁱ MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTINEOPLASTIC AGENT; DEOXYRIBOZYME; DZ 13; MESSENGER RNA; PROTEIN C JUN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; BIOASSAY; C JUN GENE; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CPG ISLAND; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG METASTASIS; MITOGENESIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TUMOR GENE; TUMOR IMMUNITY; TUMOR VASCULARIZATION; ANIMAL; DOSE RESPONSE; GENETICS; SKIN TUMOR; TUMOR CELL LINE; ZEBRA FISH;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA, CATALYTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNITY, CELLULAR; MICE; PROTO-ONCOGENE PROTEINS C-JUN; SKIN NEOPLASMS; ZEBRAFISH;

EID: 84862841985     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003960     Document Type: Article

References (42)

1. U. Leiter, C. Garbe, Epidemiology of melanoma and nonmelanoma skin cancer - The role of sunlight. Adv. Exp. Med. Biol. 624, 89-103 (2008).
2. C. S. Wong, R. C. Strange, J. T. Lear, Basal cell carcinoma. BMJ 327, 794-798 (2003).
3. A. N. Crowson, Basal cell carcinoma: Biology, morphology and clinical implications. Mod. Pathol. 19 (Suppl. 2), S127-S147 (2006).
4. R. Bhindi, R. G. Fahmy, H. C. Lowe, C. N. Chesterman, C. R. Dass, M. J. Cairns, E. G. Saravolac, L. Q. Sun, L. M. Khachigian, Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol. 171, 1079-1088 (2007).
5. L. M. Khachigian, Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J. Clin. Invest. 106, 1189-1195 (2000).
6. S. W. Santoro, G. F. Joyce, A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U.S.A. 94, 4262-4266 (1997).
7. L. M. Khachigian, DNAzymes: Cutting a path to a new class of therapeutics. Curr. Opin. Mol. Ther. 4, 119-121 (2002).
8. L. M. Khachigian, R. G. Fahmy, G. Zhang, Y. V. Bobryshev, A. Kaniaros, c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J. Biol. Chem. 277, 22985-22991 (2002).
9. E. Shaulian, M. Karin, AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400 (2001).
10. C. A. Sledz, M. Holko, M. J. de Veer, R. H. Silverman, B. R. Williams, Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839 (2003).
11. K. Kim, F. Liu, Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences. Biochim. Biophys. Acta 1769, 603-612 (2007).
12. G. M. Halliday, S. Le, Transforming growth factor-b produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int. Immunol. 13, 1147-1154 (2001).
13. G. Zhang, X. Luo, E. Sumithran, V. S. C. Pua, R. S. Barnetson, G. M. Halliday, L. M. Khachigian, Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 25, 7260-7266 (2006).
14. S. Nicoli, M. Presta, The zebrafish/tumor xenograft angiogenesis assay. Nat. Protoc. 2, 2918-2923 (2007).
15. H. T. Yen, L. C. Chiang, K. H. Wen, C. C. Tsai, C. L. Yu, H. S. Yu, The expression of cytokines by an established basal cell carcinoma cell line (BCC-1/KMC) compared with cultured normal keratinocytes. Arch. Dermatol. Res. 288, 157-161 (1996).
16. A. D. Lucas, G. M. Halliday, Progressor but not regressor skin tumours inhibit Langerhans'cell migration from epidermis to local lymph nodes. Immunology 97, 130-137 (1999).
17. S. H. Jee, S. C. Shen, H. C. Chiu, W. L. Tsai, M. L. Kuo, Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 20, 198-208 (2001).
18. M. J. Cairns, T. M. Hopkins, C. Witherington, L. Q. Sun, The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzyme. Antisense Nucleic Acid Drug Dev. 10, 323-332 (2000).
19. T. Uno, K. Takeda, Y. Kojima, H. Yoshizawa, H. Akiba, R. S. Mittler, F. Gejyo, K. Okumura, H. Yagita, M. J. Smyth, Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12, 693-698 (2006).
20. G. J. Weiner, H. M. Liu, J. E. Wooldridge, C. E. Dahle, A. M. Krieg, Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 94, 10833-10837 (1997).
21. S. Bauer, H. Wagner, Bacterial CpG-DNA licenses TLR9. Curr. Top. Microbiol. Immunol. 270, 145-154 (2002).
22. M. M. Whitmore, M. J. DeVeer, A. Edling, R. K. Oates, B. Simons, D. Lindner, B. R. Williams, Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64, 5850-5860 (2004).
23. M. Hafner, R. Zawatzky, C. Hirtreiter, W. A. Buurman, B. Echtenacher, T. Hehlgans, D. N. Männel, Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 61, 5523-5528 (2001).
24. T. L. Roberts, M. J. Sweet, D. A. Hume, K. J. Stacey, Cutting edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J. Immunol. 174, 605-608 (2005).
25. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (Food and Drug Administration, Rockville, MD, 2005).
26. K. Rass, W. Tilgen, Treatment of melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol. 624, 296-318 (2008).
27. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, M. E. Dudley, Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008).
28. + T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118, 1390-1397 (2008).
29. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. L. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. M. McLaughlin, N. M. Haynes, M. J. Smyth, G. Kroemer, L. Zitvogel, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
30. L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M. C. Maiuri, E. Ullrich, P. Saulnier, H. Yang, S. Amigorena, B. Ryffel, F. J. Barrat, P. Saftig, F. Levi, R. Lidereau, C. Nogues, J. P. Mira, A. Chompret, V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. André, S. Delaloge, T. Tursz, G. Kroemer, L. Zitvogel, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
31. + T cells. World J. Surg. 19, 352-358 (1995).
32. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010).
33. A. W. Griffioen, Anti-angiogenesis: Making the tumor vulnerable to the immune system. Cancer Immunol. Immunother. 57, 1553-1558 (2008).
34. D. J. Betting, R. E. Yamada, K. Kafi, J. Said, N. van Rooijen, J. M. Timmerman, Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J. Immunother. 32, 622-631 (2009).
35. T. W. Wong, C. H. Chen, C. C. Huang, C. D. Lin, S. W. Hui, Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J. Control. Release 110, 557-565 (2006).
36. L. M. Khachigian, D. A. Owensby, C. N. Chesterman, A tyrosinated peptide representing the alternatively spliced exon of the platelet-derived growth factor A-chain binds specifically to cultured cells and interferes with binding of several growth factors. J. Biol. Chem. 267, 1660-1666 (1992).
37. L. A. Rafty, L. M. Khachigian, Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats. J. Biol. Chem. 273, 5758-5764 (1998).
38. G. Zhang, C. R. Dass, E. Sumithran, N. R. Di Girolimo, L.-Q. Sun, L. M. Khachigian, Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J. Natl. Cancer Inst. 96, 683-696 (2004).
39. N. D. Lawson, B. M. Weinstein, In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307-318 (2002).
40. R. Sungaran, O. T. Chisholm, B. Markovic, L. M. Khachigian, Y. Tanaka, B. H. Chong, The role of platelet a-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood 95, 3094-3101 (2000).
41. H. Cai, C. Song, I. G. Lim, S. A. Krilis, C. L. Geczy, H. P. McNeil, Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases. J. Rheumatol. 32, 1224-1231 (2005).
42. Y. Cheng, W. H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).